李环球

发布时间：2026-09-04浏览次数：159

  • 1、Computational Discovery and Repurposing of Chloramphenicol Succinate as a Potent P2Y14 Receptor Antagonist for Inflammatory Bowel Disease Therapy,J Adv Res,2026, 83, 1157-1174.,一区top期刊IF:17.1,通讯作者
  • 2、Targeting P2Y14 Receptor in Inflammatory and Metabolic Diseases: From Pathophysiology to Therapeutic Inhibitors. ,Med Res Rev,2026, doi.org/10.1002/med.70066.,一区top期刊IF:13.6, 通讯作者
  • 3、A novel small-molecule inhibitor TD6 targets Prohibitin 1 (PHB1) and suppresses colorectal cancer pulmonary metastasis by disrupting mitochondrial complex I stability.,Redox Biol.,2026, 95, 104291.,一区top期刊IF:16.2,通讯作者
  • 4、Discovery of Benfotiamine as a subnanomolar P2Y14R antagonist for inflammatory diseases via drug repurposing and molecular dynamics-guided mechanism elucidation. ,Eur J Med Chem.,2026, 316, 119068.,JCR Q1, IF:6.6，通讯作者
  • 5、Calceolarioside B alleviates airway barrier dysfunction and inflammation via targeting P2Y6R in OVA-triggered asthma.,Biochem Pharmacol.,2026, 252, 118209.,JCR Q1, IF:6.5，通讯作者
  • 6、LSD1 inhibitors for anticancer therapy: an updated patent review (2022-2025). ,Expert Opin Ther Patents,2026, 36, 311-332.,JCR Q1, IF:4.9，通讯作者
  • 7、Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.,J Med Chem.,2025, 68, 14907-14918.,一区top期刊,IF:7.8,通讯作者
  • 8、Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer.,J Med Chem.,2025, 68, 17794-17807.,一区top期刊,IF:7.8,通讯作者
  • 9、Discovery of Novel P2Y14R Inhibitors for Ameliorating Liver Fibrosis by Suppressing Hepatic Stellate Cell Activation.,J Med Chem.,2025, 68, 23277–23299.,一区top期刊IF:7.8,通讯作者
  • 10、Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors.,Pharmacol Ther ,2025, 267, 108802.,一区top期刊IF:12,通讯作者
  • 11、Insights of affinity-based probes for target identification in drug discovery.,Eur J Med Chem,2025, 293, 117711.,JCR Q1, IF:6.6，通讯作者
  • 12、Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics.,J Adv Res,2025, 69, 427-488.,一区top期刊IF:13,通讯作者
  • 13、Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis.,Nat Commun ,2024, 15, 2083. ,一区top期刊 IF:16.6,通讯作者
  • 14、Macrophage P2Y6R activation aggravates psoriatic inflammation through IL-27-mediated Th1 responses. ,Acta Pharma Sin B,2024, 14, 4360-4377.,一区top期刊 IF = 14.7,通讯作者
  • 15、Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase C尾/store-operated calcium entry/calreticulin/scavenger receptor A pathways.,Eur Heart J ,2024, 45, 268–283.,一区top期刊IF:38.8,共同一作
  • 16、Discovery of novel FUT8 inhibitors with promising affinity and in vivo efficacy for colorectal cancer therapy.,Bioorgan Chem ,2024, 149, 104492.,二区top,通讯作者
  • 17、Network pharmacology-based analysis of Jin-Si-Wei on the treatment of Alzheimer's disease.,J Ethnopharmacol ,2024, 319, 117291.,二区top,通讯作者
  • 18、Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches.,Chem Bio Drug Des,2024,104:e14607,通讯作者
  • 19、Discovery of Selective P2Y6R Antagonists with High-Affinity and In Vivo Efficacy for Inflammatory Diseases Therapy.,J Med Chem. ,2023, 66, 6315-6332.,一区top期刊,IF:7.8,通讯作者
  • 20、Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist.,Phytomedicine.,2023, 115, 154851.,一区top期刊IF:7.9,通讯作者
  • 21、FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.,Cell Death Dis,2023, 14(8): 495.,一区top期刊IF:9.8,通讯作者